Novartis Sues Dr. Reddy's, Watson Over ANDAs For Generic Exelon

Law360, New York (August 16, 2004, 12:00 AM EDT) -- Swiss pharmaceutical giant Novartis has filed two separate patent infringement lawsuits against generic makers Dr. Reddy’s and Watson Pharmaceuticals in response to their plans to make generic versions of Alzheimer treatment Exelon.

Novartis and its subsidiaries sued Dr. Reddy’s in the U.S. District Court for the Southern District of New York on Aug. 4 and, separately, Watson in the Central District of California on Aug. 6.

Both cases claim patent infringement in response to filings of Abbreviated New Drug Applications (ANDAs) with the U.S. Food and...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.